Processa Pharmaceuticals (PCSA) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $1.69, +0.60% vs the prior close of $1.68.
- Volume 22.05K shares, 0.2x its 50-day average (light).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
PCSA rises 0.6% to $1.69. Closed at $1.69, +0.60% vs the prior close of $1.68. Day range $1.61–$1.74, opened at $1.69.
PCSA daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — PCSA rises 0.6% to $1.69
- Closed at $1.69, +0.60% vs the prior close of $1.68. Day range $1.61–$1.74, opened at $1.69.
- Volume was 22.05K shares, 0.2x its 50-day average of 101.38K — lighter than usual.
- Price is -14.0% vs its 50-day average ($1.96) and -30.5% vs its 200-day average ($2.43).
- 52-week range $1.04–$10.85; today's close sits at 7% of that range, 84.4% below the 52-week high.
Oct 15, 2026 — PCSA jumps 4.0% to $1.68
- Closed at $1.68, +4.02% vs the prior close of $1.62. Day range $1.53–$1.72, opened at $1.58.
- Volume was 31.10K shares, 0.3x its 50-day average of 102.07K — lighter than usual.
- Price is -15.0% vs its 50-day average ($1.98) and -31.1% vs its 200-day average ($2.44).
- 52-week range $1.04–$11.00; today's close sits at 6% of that range, 84.7% below the 52-week high.
Oct 14, 2026 — PCSA slides 8.8% to $1.62
- Closed at $1.62, -8.76% vs the prior close of $1.77. Day range $1.56–$1.75, opened at $1.75.
- Volume was 46.30K shares, 0.4x its 50-day average of 104.19K — lighter than usual.
- Price is -18.7% vs its 50-day average ($1.99) and -34.0% vs its 200-day average ($2.45).
- 52-week range $1.04–$11.00; today's close sits at 6% of that range, 85.3% below the 52-week high.
Oct 13, 2026 — PCSA slides 6.8% to $1.77
- Closed at $1.77, -6.84% vs the prior close of $1.90. Day range $1.77–$1.93, opened at $1.93.
- Volume was 69.20K shares, 0.7x its 50-day average of 104.76K.
- Price is -11.4% vs its 50-day average ($2.00) and -28.0% vs its 200-day average ($2.46).
- 52-week range $1.04–$11.07; today's close sits at 7% of that range, 84.0% below the 52-week high.
Oct 12, 2026 — PCSA jumps 25.0% to $1.90 on 4.2x normal volume
- Closed at $1.90, +25.00% vs the prior close of $1.52. Day range $1.50–$1.98, opened at $1.56.
- Volume was 438.30K shares, 4.2x its 50-day average of 103.91K — unusually heavy trading.
- Price is -5.2% vs its 50-day average ($2.00) and -23.0% vs its 200-day average ($2.47).
- 52-week range $1.04–$11.07; today's close sits at 9% of that range, 82.8% below the 52-week high.
Oct 9, 2026 — PCSA jumps 12.6% to $1.52 on 55.4x normal volume
- Closed at $1.52, +12.59% vs the prior close of $1.35. Day range $1.04–$1.87, opened at $1.32.
- Volume was 2.97M shares, 55.4x its 50-day average of 53.63K — unusually heavy trading.
- Price is -24.3% vs its 50-day average ($2.01) and -38.6% vs its 200-day average ($2.48).
- 52-week range $1.04–$11.07; today's close sits at 5% of that range, 86.3% below the 52-week high.
- SEC filings that day: S-3.
Oct 8, 2026 — PCSA slides 4.9% to $1.35, a 52-week low
- Closed at $1.35, -4.93% vs the prior close of $1.42. Day range $1.32–$1.43, opened at $1.42.
- Volume was 12.80K shares, 0.0x its 50-day average of 265.51K — lighter than usual.
- Price is -33.1% vs its 50-day average ($2.02) and -45.7% vs its 200-day average ($2.49).
- 52-week range $1.32–$14.25; today's close sits at 0% of that range, 90.5% below the 52-week high.
Oct 7, 2026 — PCSA slides 6.6% to $1.42, a 52-week low
- Closed at $1.42, -6.58% vs the prior close of $1.52. Day range $1.41–$1.53, opened at $1.53.
- Volume was 12.90K shares, 0.0x its 50-day average of 268.03K — lighter than usual.
- Price is -30.2% vs its 50-day average ($2.03) and -43.2% vs its 200-day average ($2.50).
- 52-week range $1.41–$14.25; today's close sits at 0% of that range, 90.0% below the 52-week high.
Oct 6, 2026 — PCSA rises 2.0% to $1.52
- Closed at $1.52, +2.01% vs the prior close of $1.49. Day range $1.45–$1.59, opened at $1.51.
- Volume was 17.90K shares, 0.1x its 50-day average of 268.90K — lighter than usual.
- Price is -26.4% vs its 50-day average ($2.07) and -39.5% vs its 200-day average ($2.51).
- 52-week range $1.45–$14.25; today's close sits at 1% of that range, 89.3% below the 52-week high.
Oct 5, 2026 — PCSA slides 7.5% to $1.49, a 52-week low, 8 down days in a row
- Closed at $1.49, -7.45% vs the prior close of $1.61. Day range $1.49–$1.63, opened at $1.56.
- Volume was 25.70K shares, 0.1x its 50-day average of 270.97K — lighter than usual.
- Price is -28.6% vs its 50-day average ($2.09) and -41.3% vs its 200-day average ($2.54).
- 52-week range $1.49–$14.25; today's close sits at 0% of that range, 89.5% below the 52-week high.
- That makes 8 straight losses.
Oct 2, 2026 — PCSA dips 0.6% to $1.61, a 52-week low, 7 down days in a row
- Closed at $1.61, -0.62% vs the prior close of $1.62. Day range $1.60–$1.74, opened at $1.73.
- Volume was 14.90K shares, 0.1x its 50-day average of 272.76K — lighter than usual.
- Price is -23.7% vs its 50-day average ($2.11) and -36.7% vs its 200-day average ($2.54).
- 52-week range $1.57–$14.25; today's close sits at 0% of that range, 88.7% below the 52-week high.
- That makes 7 straight losses.
PCSA latest news & SEC filings
Every SEC filing by or about PCSA in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 9, 2026 · Form PRE 14A — Preliminary proxy statement
Preliminary proxy statement
Oct 9, 2026 · Form PRE 14A — Preliminary proxy statement
Preliminary proxy statement
Oct 9, 2026 · Form S-3 — Shelf registration (S-3)
Shelf registration (S-3) — lets the company sell securities over time
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Oct 5, 2026 · Form 8-K/A — Current report (amended)
Amended current report
- Item 8.01 — Reported other events the company considers important.
Aug 18, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$3.27M (prior year -$3.93M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$1.19 (prior year -$6.26) (loss narrowed vs Jun 30, 2025)
Aug 11, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 4, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
- Item 5.07 — Reported shareholder vote results.
Jul 30, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 30, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Jul 29, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 1.02 — Ended a material agreement.
- Item 2.01 — Completed an acquisition or sale of assets.
- Item 3.02 — Sold unregistered shares.
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
- Item 5.03 — Amended its charter or bylaws / changed fiscal year.
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Jul 28, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 28, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 28, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Things to know before you trade PCSA
- Last results release: Mar 31, 2023 (8-K Item 2.02). Previous ones: Nov 8, 2022, Aug 12, 2022, Aug 13, 2021. Based on that rhythm, the next report is likely around Jun 30, 2023 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 5.16% (largest 25.0%). That is a volatile stock.
- Liquidity: about 194.12K shares (≈$328.07K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $1.69 vs a range of $1.04–$10.85 (7% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: 1:25 on Dec 17, 2025
- Insider trades (Form 4, last 12 months, recent 25 shown): 25 open-market buys, 0 sales; latest: George K Ng bought 3,057 shares on Jul 1, 2026.
- Latest filings: 10-Q Aug 14, 2026; 8-K Aug 4, 2026; 8-K Jul 29, 2026.
- Share count: 2.79M shares outstanding (Aug 7, 2026), -94.5% vs a year earlier — the company has been reducing its share count.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
PCSA market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 1.69 | 1.74 | 1.61 | 1.69 | 22.05K |
| Oct 15, 2026 | 1.58 | 1.72 | 1.53 | 1.68 | 31.10K |
| Oct 14, 2026 | 1.75 | 1.75 | 1.56 | 1.62 | 46.30K |
| Oct 13, 2026 | 1.93 | 1.93 | 1.77 | 1.77 | 69.20K |
| Oct 12, 2026 | 1.56 | 1.98 | 1.50 | 1.90 | 438.30K |
| Oct 9, 2026 | 1.32 | 1.87 | 1.04 | 1.52 | 2.97M |
| Oct 8, 2026 | 1.42 | 1.43 | 1.32 | 1.35 | 12.80K |
| Oct 7, 2026 | 1.53 | 1.53 | 1.41 | 1.42 | 12.90K |
| Oct 6, 2026 | 1.51 | 1.59 | 1.45 | 1.52 | 17.90K |
| Oct 5, 2026 | 1.56 | 1.63 | 1.49 | 1.49 | 25.70K |
| Oct 2, 2026 | 1.73 | 1.74 | 1.60 | 1.61 | 14.90K |
| Oct 1, 2026 | 1.59 | 1.64 | 1.57 | 1.62 | 10.20K |
| Sep 30, 2026 | 1.83 | 1.85 | 1.57 | 1.64 | 84.10K |
| Sep 29, 2026 | 1.76 | 1.83 | 1.75 | 1.76 | 9.30K |
| Sep 28, 2026 | 1.84 | 1.84 | 1.77 | 1.84 | 9.40K |
| Sep 25, 2026 | 1.88 | 1.93 | 1.80 | 1.84 | 8.50K |
| Sep 24, 2026 | 1.89 | 1.94 | 1.80 | 1.85 | 5.10K |
| Sep 23, 2026 | 1.90 | 1.97 | 1.87 | 1.89 | 4.70K |
| Sep 22, 2026 | 1.91 | 2.02 | 1.85 | 1.88 | 74.50K |
| Sep 21, 2026 | 1.87 | 1.94 | 1.84 | 1.84 | 16.50K |
About Processa Pharmaceuticals
Processa Pharmaceuticals (PCSA) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in VERO BEACH, FL. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1533743.
PCSA board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Khoso Baluch | Director | Jul 28, 2026 |
| Sheila Gujrathi | Director | Jul 30, 2026 |
| James R Neal | Director | Jul 28, 2026 |
| George K Ng | Chief Executive Officer | Aug 11, 2026 |
| Geraldine Pannu | Director | Jul 28, 2026 |
| Justin W Yorke | Director | Jul 28, 2026 |
| David Young | Pres. Research & Development | Jul 1, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Sian Bigora | Chief Development Officer | May 19, 2026 |
| Wendy Guy | Chief Administrative Officer | Jul 28, 2026 |
| Patrick Lin | Chief Business - Strategy Off | Jul 28, 2026 |
| George K Ng | Chief Executive Officer | Aug 11, 2026 |
| Russell Skibsted | Chief Financial Officer | Jul 28, 2026 |
| David Young | Pres. Research & Development | Jul 1, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jul 1, 2026 | George K Ng | Buy | 3,057 | $1.93 |
| Jul 1, 2026 | George K Ng | Buy | 3,057 | $1.93 |
| Jul 1, 2026 | George K Ng | Buy | 3,057 | $1.93 |
| Jul 1, 2026 | George K Ng | Buy | 3,057 | $1.93 |
| Jun 30, 2026 | David Young | Buy | 2,531 | $1.93 |
| Jun 30, 2026 | David Young | Buy | 2,531 | $1.93 |
| Jun 30, 2026 | David Young | Buy | 2,531 | $1.93 |
| Jun 30, 2026 | David Young | Buy | 2,531 | $1.93 |
| Jun 30, 2026 | Patrick Lin | Buy | 2,106 | $1.93 |
| Jun 30, 2026 | Patrick Lin | Buy | 2,106 | $1.93 |
| Jun 30, 2026 | Patrick Lin | Buy | 2,106 | $1.93 |
| Jun 30, 2026 | Patrick Lin | Buy | 2,106 | $1.93 |
| Jun 30, 2026 | Russell Skibsted | Buy | 3,277 | $1.93 |
| Jun 30, 2026 | Russell Skibsted | Buy | 3,277 | $1.93 |
| Jun 30, 2026 | Russell Skibsted | Buy | 3,277 | $1.93 |
PCSA financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-13.56M | -10.36 | $-11.39M |
| Dec 31, 2024 | — | $-11.85M | -96.78 | $-11.25M |
| Dec 31, 2023 | — | $-11.12M | -8.48 | $-8.06M |
| Dec 31, 2022 | $0 | $-27.42M | -34.05 | $-9.61M |
| Dec 31, 2021 | $0 | $-11.43M | — | $-8.72M |
Latest balance sheet: total assets $2.07M, total liabilities $2.39M, cash $196.32K (as of Jun 30, 2026).
PCSA earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Mar 31, 2023 | 8-K Item 2.02 (results) | — |
| Nov 8, 2022 | 8-K Item 2.02 (results) | — |
| Aug 12, 2022 | 8-K Item 2.02 (results) | — |
| Aug 13, 2021 | 8-K Item 2.02 (results) | — |
| May 13, 2021 | 8-K Item 2.02 (results) | — |
| Mar 25, 2021 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on PCSA
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.